Mattia Bonsignori

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
  2. pmc HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
  3. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
  4. pmc HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
  5. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
  6. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
  7. pmc Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 87:7828-36. 2013
  8. pmc Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
    Georgia D Tomaras
    Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:9019-24. 2013
  9. pmc Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
    S Munir Alam
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 87:1554-68. 2013
  10. pmc Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, P O Box 2926, Durham, NC 27710, USA
    Curr HIV Res 11:378-87. 2013

Collaborators

Detail Information

Publications12

  1. pmc Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
    ..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs...
  2. pmc HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
    ..Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design...
  3. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
    ..These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities...
  4. pmc HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
    ..The inability to generate high titers of long-lived anti-envelope Abs is a major hurdle to overcome for the development of a successful HIV-1 vaccine...
  5. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  6. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  7. pmc Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 87:7828-36. 2013
    ..Although capture of infectious HIV-1 correlated with other humoral immune responses, the extent of variation between these humoral responses and virion capture indicates that virion capture antibodies occupy unique immunological space. ..
  8. pmc Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
    Georgia D Tomaras
    Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:9019-24. 2013
    ..We show that monomeric Env-specific IgA, as part of postvaccination polyclonal antibody response, may modulate vaccine-induced immunity by diminishing ADCC effector function...
  9. pmc Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
    S Munir Alam
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 87:1554-68. 2013
    ..These results demonstrate that deletion of N-terminal residues in the RV144 A244 gp120 immunogen improves both envelope antigenicity and immunogenicity...
  10. pmc Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, P O Box 2926, Durham, NC 27710, USA
    Curr HIV Res 11:378-87. 2013
    ..Here we discuss the HIV-1 envelope epitopes targeted by ADCC antibodies in the context of the potential protective capacities of ADCC. ..
  11. pmc Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
    ..No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials...
  12. pmc Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors
    S Munir Alam
    Duke Human Vaccine Institute and Departments of Medicine, Pathology, and Immunology, Duke University Medical Center, Durham, NC 27710
    Proc Natl Acad Sci U S A 110:18214-9. 2013
    ....